ERBB2 and breast cancer: Although mono anti-HER2 antibody combined with single-agent chemotherapy has become a recommended adjuvant regimen for node-negative, small HER2-positive tumors, there is scarcity of evidence on TKIs for HER2 + low-risk breast cancer.